Effects of Rosiglitazone on Serum Ghrelin and Peptide YY Levels
NCT00522470 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL
Last updated 2008-05-09
Summary
We aimed to evaluate the effects of rosiglitazone on serum ghrelin and peptide yy levels in diabetic women.
Conditions
Interventions
- DRUG
-
rosiglitazone
Sponsors & Collaborators
-
Baskent University
lead OTHER
Principal Investigators
-
Zehra Berberoglu, MD · Baskent University Faculty of Medicine
Study Design
- Allocation
- RANDOMIZED
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 45 Years
- Max Age
- 65 Years
- Sex
- FEMALE
- Healthy Volunteers
- No
Timeline & Regulatory
Countries
- Turkey (Türkiye)
Study Locations
More Related Trials
-
Comparison of Repaglinide and Gliclazide in Chinese Subjects With Type 2 Diabetes Never Received Oral Antidiabetic Drug Treatment
NCT01022762 ·Status: COMPLETED ·Phase: PHASE4
-
Rosiglitazone In Subjects With Type 2 Diabetes Mellitus Who Are Inadequately Controlled On Insulin
NCT00329225 ·Status: COMPLETED ·Phase: PHASE4
-
Effect of Rosiglitazone on the Vascular Biology of Human Fat Tissue
NCT01150981 ·Status: COMPLETED ·Phase: PHASE2
-
A Clinical Study to Evaluate Safety, Tolerability and Pharmacokinetics of Oral ZYGK1 in Healthy Volunteers
NCT01472809 ·Status: SUSPENDED ·Phase: PHASE1
-
Effects of Rosiglitazone and Metformin on Metabolism in Type 2 Diabetes
NCT02526615 ·Status: COMPLETED ·Phase: PHASE4
-
A Study Of Rosiglitazone Plus Insulin To Treat Type 2 Diabetes Mellitus Patients
NCT00349427 ·Status: COMPLETED ·Phase: PHASE3
-
The Influencing Factors of 12 Week Efficacy of Polyethylene Glycol Losenatide in Type 2 Diabetes Patients
NCT05611684 ·Status: RECRUITING ·Phase: PHASE4
-
Placebo Controlled Dose-Response Study of Rivoglitazone in Type 2 Diabetes
NCT00575471 ·Status: COMPLETED ·Phase: PHASE2
-
Glibenclamide (Dose to be Titrated From Starting Dose of 5mg om) Plus Rosiglitazone 4mg om (Increased to 8mg om After 6 Months) and vs Glibenclamide (Dose to be Titrated With Starting Dose of 5mg om) Plus Placebo, Administered to Patients With Type 2 Diabetes Mellitus
NCT01045590 ·Status: COMPLETED ·Phase: PHASE4
-
Effect of Adiponectin Genetic Polymorphism on Rosiglitazone Response
NCT00501488 ·Status: COMPLETED
-
24-Hour Glycemia: Rosiglitazone Versus Glimepiride In Type 2 Diabetes
NCT00318656 ·Status: COMPLETED ·Phase: PHASE4
-
Efficacy and Safety Study of Rosiglitazone/Metformin Therapy vs Rosiglitazone and Metformin in Type 2 Diabetes Subjects
NCT00499707 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy and Safety of Treatment With Balaglitazone in Type 2 Diabetes Patients on Stable Insulin Therapy
NCT00515632 ·Status: COMPLETED ·Phase: PHASE3
-
An Efficacy and Safety Study of Fixed-dose Rosiglitazone/Glimepiride to Treat Chinese Type 2 Diabetes Patients
NCT01453049 ·Status: TERMINATED ·Phase: PHASE3
-
A Trial In Diabetic Patients To Assess Effect Of CE-326,597 On Glucose Control And Body Weight
NCT00542009 ·Status: COMPLETED ·Phase: PHASE2
-
Effect of Mizagliflozin Repeat Dosing on Adverse Events and Postprandial Glucose Excursions
NCT05721729 ·Status: COMPLETED ·Phase: PHASE2
-
Rosiglitazone to Reverse Metabolic Defects in Diabetes
NCT00094796 ·Status: COMPLETED ·Phase: PHASE2
-
Role of Rosiglitazone on Pre-Diabetes Mellitus and Coronary Artery Disease
NCT01574820 ·Status: COMPLETED ·Phase: PHASE3
-
Rosiglitazone-Induced Weight Gain
NCT00225225 ·Status: TERMINATED ·Phase: NA
-
Predictive Markers of Glitazone Efficacy in Diabetic Patients - Pilot Study
NCT00481429 ·Status: WITHDRAWN
-
Effects of Pioglitazone in Hypertensive Patients
NCT01472497 ·Status: COMPLETED ·Phase: PHASE4
-
Efficacy and Safety of Chiglitazar Added to Glargine in Patients With Type 2 Diabetes
NCT06007014 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Dose Response Study in Japanese Patients
NCT00261417 ·Status: TERMINATED ·Phase: PHASE2
-
Effects of Rosiglitazone on Bone in Postmenopausal Diabetic Women
NCT00440375 ·Status: COMPLETED ·Phase: PHASE4
-
Investigation of Vascular Relaxing Effects of the Antidiabetic Rosiglitazone.
NCT00154011 ·Status: COMPLETED ·Phase: NA